|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Dr. Jeffrey Nau Ph.D., MMS||Pres, CEO & Director||833,6k||N/A||1975|
|Mr. Daniel Lochner M.B.A.||Chief Financial Officer||644,68k||N/A||1983|
|Mr. John Snisarenko M.B.A.||Chief Commercial Officer||604,68k||N/A||1964|
|Mr. George Donato||Sr. VP of CMC & Operations||N/A||N/A||N/A|
|Dr. Eric Carlson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Jill Andersen J.D.||Gen. Counsel, Corp. Sec. & Chief Compliance Officer||N/A||N/A||N/A|
|Ms. Loni Da Silva||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Marian Macsai M.D.||Chief Medical Officer of Medical Affairs||N/A||N/A||N/A|
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
El ISS Governance QualityScore de Oyster Point Pharma, Inc., a día 26 de septiembre de 2021, es 9. Las puntuaciones base son Auditoría: 6; Tablero: 9; Derechos de los accionistas: 8; Compensación: 10.